Highlights Abivax

Equities

ABVX

FR0012333284

Real-time Euronext Paris Other stock markets 03:13:33 08/05/2024 pm IST			5-day change	1st Jan Change
13.78 ^EUR	-1.71%		+0.14%	+40.94%

08:30am	Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024	CI
29/04	Abivax: share price rises as two analysts express optimism	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024	12:00pm	CI
ABIVAX Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn?s Disease	02/02	CI
Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis	24/01	CI
Abivax: share price rises after strategic update	22/01	CF
Abivax Raises $235.8 Million via Nasdaq IPO	25/23/25	MT
Abivax Closes Nasdaq IPO With $235.8 Million in Gross Proceeds	25/23/25	MT
Abivax Prices Nasdaq IPO; Trading Resumes in Paris	20/23/20	MT
Abivax: Nasdaq IPO price at bottom of range	20/23/20	CF
Abivax Shares Temporarily Suspended from Trading on Euronext Paris	20/23/20	MT
Abivax Sets Price Range for Public Offering of American Depositary Shares in US	19/23/19	MT
Abivax Files for Public Offering of American Depositary Shares in US	02/23/02	MT
ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.	29/23/29	CI
ABIVAX Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	21/23/21	CI
ABIVAX Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD	20/22/20	CI
ABIVAX Société Anonyme completed the acquisition of Prosynergia.	12/22/12	CI
Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis	11/22/11	CI
ABIVAX Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2022	15/22/15	CI
Abivax SA Announces Phase 2B Study Results of Obefazimod in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology	06/22/06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Abivax

Equities

ABVX

FR0012333284

Highlights

Filters